Breakthrough Clinical Results
Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi (glofitamab) plus GemOx compared to MabThera/Rituxan plus GemOx. The study demonstrated a statistically significant and clinically meaningful survival benefit, with a 59% reduction in the risk of disease progression or death. The benefit was maintained across key secondary endpoints, including progression-free survival and complete remission. Columvi's combination with GemOx is approved in over 30 countries for R/R DLBCL patients not eligible for autologous stem cell transplant and is an NCCN category 1 preferred recommendation for second-line treatment.
Key Highlights
- 40% improvement in overall survival with Columvi + GemOx vs. MabThera/Rituxan + GemOx in R/R DLBCL patients.
- 59% reduction in the risk of disease progression or death with Columvi + GemOx.
- 89% of patients with complete remission at the end of treatment were still alive after one year.
- Columvi + GemOx combination approved in over 30 countries for R/R DLBCL patients ineligible for ASCT.
Latest Estimates of Incidence and Prevalence of Diffuse Large B-cell Lymphoma Globally
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma (NHL) worldwide, accounting for 30% of adult non-Hodgkin lymphomas. Non-Hodgkin lymphomas constitute about 90% of an estimated 3%-4% worldwide distribution of malignant lymphomas among various cancers.
The incidence of NHL is variable and affected by age, gender, racial, and geographic factors. Regional prevalence data shows significant variations:
- In Sabah, Malaysia, DLBCL was found to be the most prevalent type, accounting for 65.1% of NHL cases
- In Ghana, DLBCL constitutes the predominant group (40.9%) among NHL subtypes
- In Pakistan, from a study conducted between 2015-2020, only 6.4% of DLBCL cases were recognized as anaplastic variants
- Epstein-Barr virus (EBV)-positive DLBCL of the elderly accounts for 8-10% of DLBCLs in Asian countries, but is less common in Western populations
In the United States, a study estimated DLBCL prevalence ranging from 63,883 to 142,889 depending on cure rate assumptions (52.8% to 68.9%). With an assumption of no cure, estimated prevalence in the US was 179,475.
Multiple studies have demonstrated race-based disparities in survival among patients with DLBCL across all stages of disease. African Americans with DLBCL may have a poorer prognosis than non-African American populations.
Emerging Mechanisms of Action for Diffuse Large B-cell Lymphoma
Anti-CD19 Antibody-Drug Conjugate Therapy
- Loncastuximab tesirine-lpyl from ADC Therapeutics was recently approved for relapsed/refractory DLBCL
- This anti-CD19 antibody-drug conjugate uses pyrrolobenzodiazepine (PBD) as an effective payload
- Demonstrated efficacy in high-risk DLBCL subgroups with tolerable side effects in elderly patients (≥75 years)
B-cell Receptor (BCR) Signaling Inhibitors
- Novel therapeutic approaches include inhibitors of B-cell receptor signaling
-
CK2 inhibitor (CX-4945) demonstrated effectiveness by:
-
Causing DLBCL cell death
-
Impairing AKT phosphorylation and intracellular Ca++ mobilization upon BCR engagement
-
Acting synergistically with SYK inhibitor (Fostamatinib) or BTK inhibitor (Ibrutinib)
-
Being equally effective in GC and ABC DLBCL subtypes and "double hit" DLBCL cell lines
BCL-2 Inhibition Approaches
- Venetoclax (selective BCL-2 inhibitor) showed response in a minority of patients
-
Combination therapy of decitabine (DNA hypomethylating agent) and venetoclax:
-
Decitabine increased mitochondrial apoptotic priming and BCL-2 dependence
-
Decitabine suppressed pro-survival PI3K-AKT pathway and altered mitochondria membrane composition
-
The combination synergistically suppressed DLBCL cell proliferation both in vitro and in vivo
PKCbeta Inhibition
- Enzastaurin, a potent PKCbeta inhibitor, was well-tolerated in relapsed/refractory DLBCL
- Associated with prolonged freedom from progression in a small subset of patients
Cyclin-dependent Kinase Inhibition
- Seliciclib (CYC202, R-roscovitine), a purine analog inhibitor of CDK2/cyclin E, CDK7/cyclin H and CDK9/cyclin T
- Demonstrated in vitro activity in DLBCL cell lines (IC50 ranged from 13-36 μM)
- Effectiveness was independent of underlying chromosomal translocations characteristic of DLBCL
Deubiquitinase Inhibition
- OTUD3 (a deubiquitinase enzyme) is overexpressed in DLBCL tissues
- Enhances cell survival through deubiquitination of MYL12A and induces CD8+ T cell exhaustion by deubiquitinating PD-L1
- Rupatadine (OTUD3 inhibitor) diminishes deubiquitination of both MYL12A and PD-L1
Additional Emerging Therapies
- New anti-CD20 monoclonal antibody (IMMU-106/hA20)
- Anti-CD22 monoclonal antibody (epratuzumab)
- Radioimmunotherapy (Y-90 ibritumomab and I-131 tositumomab)
- Bortezomib in combination with R-CHOP therapy (RB-CHOP)
Study Design Parameters and Endpoints in Key DLBCL Trials
Study Design Parameters
Key trials in diffuse large B-cell lymphoma (DLBCL) typically include:
- Phase 2, single-arm and multicenter trials evaluating novel therapies for relapsed/refractory DLBCL
- Randomized controlled trials comparing treatments like Pola-BR with other interventions
- Treatment durations consisting of multiple cycles (28-day cycles common)
- Patient recruitment with specific characteristics (e.g., age ≥60 years, relapsed/refractory status)
Common Trial Endpoints
DLBCL trials consistently measure:
- Overall survival (OS)
- Progression-free survival (PFS)
- Overall response rate (ORR)
- Complete response (CR) rate
- Safety and toxicity profiles
- Freedom from progression (FFP)
Key Trials
(90)Y-ibritumomab Tiuxetan Trial
- Enrolled 55 high-risk elderly patients (age >60 years)
- Treatment: 4 cycles of R-CHOP21 followed by (90)Y-ibritumomab tiuxetan
- Primary endpoints: overall response rate (80%), including 73% complete remissions
- Secondary endpoints: 2-year PFS of 85% and 2-year OS of 86%
Enzastaurin Phase 2 Study
- Included 55 patients (median age 68 years) with 1-5 prior therapies
- Primary endpoints: freedom from progression (FFP) and objective response
- Results: 22% of patients achieved FFP for two cycles, 15% for four cycles
Lenalidomide plus Rituximab Trial
- Enrolled 23 heavily pretreated elderly patients (≥65 years)
- Treatment regimen: Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) plus rituximab (375 mg/m²) on days 1 and 21
- Achieved overall response rate of 35% after induction phase
BTKi Combination Study
- Investigated zanubrutinib or orelabrutinib combined with R-CHOP or R² in newly diagnosed MYD88/CD79B DLBCL
- Enrolled 23 newly diagnosed DLBCL patients with MYD88 and/or CD79B mutations
-
Results: Improved outcomes with BTKi+R-CHOP compared to R-CHOP alone:
-
ORR: 100% vs 70.6%
-
CRR: 94.4% vs 52.9%
-
1-year PFS rate: 88.9% vs 41.2%
These trials demonstrate the evolution of DLBCL treatment approaches, with consistent measurement of response rates, survival outcomes, and safety profiles across different patient populations.
